Drug intelligence / Profile preview

CZ-1408

Development stage: Preclinical
Lead developer: Oxidien Pharmaceuticals
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

CZ-1408 is an investigational oxalate-degrading enzyme under clinical development by Oxidien Pharmaceuticals. It is being developed for the treatment of secondary and enteric hyperoxaluria. The drug originated from the enzyme intellectual property of Captozyme, a company that previously focused on developing oxalate-degrading enzymes, such as Nephure, to assist individuals in managing low-oxalate diets for conditions like kidney stones.

Beyond the preview

Go deeper on CZ-1408.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CZ-1408.

Explore the full profile